Quantcast

Latest Triple-negative breast cancer Stories

2011-03-02 12:48:24

New findings published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research, confirm the risk of breast cancer among women who are obese and not physically active, and suggests additional mechanisms beyond estrogen. Scientists from the Women's Health Initiative have found a relationship between obesity, physical activity and triple-negative breast cancer, a subtype of breast cancer characterized by a lack of estrogen, progesterone and...

2011-03-02 09:05:03

(Ivanhoe Newswire) "“ Obesity and inactiveness may increase the risk of triple-negative breast cancer, a subtype of breast cancer characterized by lack of estrogen, progesterone, and HER2 expression. Triple-negative breast cancers account for about 10 to 20 percent of all breast cancers and are associated with an extremely poor prognosis because of the lack of targeted drug therapies. "Breast cancer is not just one disease. It is a complex combination of many diseases," Amanda Phipps,...

2011-03-01 07:30:00

WALTHAM, Mass., March 1, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced the National Cancer Institute (NCI) will sponsor a multi-center phase 2 study of Syndax's lead product entinostat, a novel inhibitor of histone deacetylases (HDAC), and anastrozole, an aromatase inhibitor, in postmenopausal women with operable triple negative breast cancer to evaluate biomarkers and surrogates for response. The trial, to be conducted under a...

2011-02-25 12:41:00

SEATTLE, Feb. 25, 2011 /PRNewswire/ -- Full-term pregnancy has long been associated with a reduced risk of breast cancer, but a new study finds that the more times a woman gives birth, the higher her risk of "triple-negative" breast cancer, a relatively uncommon but particularly aggressive subtype of the disease. Conversely, women who never give birth have a 40 percent lower risk of such breast cancer, which has a poorer prognosis than other types of breast cancer and doesn't respond to...

2011-02-24 13:02:00

NEW HAVEN, Conn., Feb. 24, 2011 /PRNewswire/ -- Mira Dx announced today that it has licensed technology from Yale University based on the acceptance of a pivotal breast cancer study in the January issue of the journal Cell Cycle. While numerous BRCA1 coding sequence mutations are associated with breast cancer risk, such mutations in BRCA1 account for less than 5% of breast cancer risk. The research identified microRNA disrupting variants in and around BRCA1 that are polymorphic in breast...

2011-02-07 14:00:00

GLENWILLOW, Ohio, Feb. 7, 2011 /PRNewswire/ -- Dots, LLC announced today that it will donate $91,086 to Susan G. Komen for the Cure® to help fund ground-breaking research and life-saving community outreach projects through the "Girlfriends Giving Back" partnership program. (Photo: http://photos.prnewswire.com/prnh/20110207/CL43584 ) (Logo: http://photos.prnewswire.com/prnh/20081202/CLTU086LOGO ) Only in its second year, the Dots "Girlfriends Giving Back" program...

2011-01-31 10:24:00

FREDERICKSBURG, Va., Jan. 31, 2011 /PRNewswire/ -- Research to develop more effective treatments for triple negative breast cancer -- a difficult disease to cure -- could someday benefit all breast cancer patients, reports Dr. Frederick C. Tucker, Jr. of Fredericksburg Oncology. "Understanding how triple negative cancers spread in the absence of normal growth factors may give us insight into how other types of breast cancer grow and spread even after treatment," Dr. Tucker explains....

2011-01-27 15:40:00

BRIDGEWATER, N.J., Jan. 27, 2011 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and its subsidiary, BiPar Sciences, today announced that a randomized Phase III trial evaluating iniparib* (BSI-201) in patients with metastatic triple-negative breast cancer (mTNBC) did not meet the pre-specified criteria for significance for co-primary endpoints of overall survival and progression-free survival. Importantly, the results of a pre-specified analysis in patients treated in the...

2011-01-05 16:00:00

BRIDGEWATER, N.J., Jan. 5, 2011 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and its wholly-owned subsidiary, BiPar Sciences, today announced that The New England Journal of Medicine (NEJM) published the final phase II data for the investigational drug iniparib* (BSI-201) demonstrating significant clinical benefit in women with metastatic triple negative breast cancer (mTNBC) when iniparib was administered in combination with chemotherapy agents gemcitabine/carboplatin....

2010-12-10 17:30:00

WALTHAM, Mass., Dec. 10, 2010 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces results from two preclinical studies on entinostat, an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor, in animal models of breast cancer. The data are being presented as oral poster discussions at the San Antonio Breast Cancer Symposium December 8 through December 12 in San Antonio Texas. The following poster discussions...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related